Download PDF
CC BY 4.0 · Journal of Health and Allied Sciences NU 2023; 13(03): 380-388
DOI: 10.1055/s-0042-1757445
Original Article

Free-androgen Index in Women with Polycystic Ovarian Syndrome: A Meta-Analysis

Prakash Patil
1   Central Research Laboratory, KS Hegde Medical Academy, Nitte (Deemed to be University), Mangaluru, Karnataka, India
,
Neevan D'Souza
2   Center for Bioinformatics and Biostatistics, Nitte (Deemed to be University), Mangaluru, Karnataka, India
,
Sudeep D. Ghate
2   Center for Bioinformatics and Biostatistics, Nitte (Deemed to be University), Mangaluru, Karnataka, India
,
Lakshmi Nagendra 
3   Department of Endocrinology, Justice KS Hegde Charitable Hospital, K S Hegde Medical Academy, Nitte (Deemed to be University), Mangaluru, Karnataka, India
,
Harish B. Girijashankar
4   Department of Anesthesiology, Justice KS Hegde Charitable Hospital, K S Hegde Medical Academy, Nitte (Deemed to be University), Mangaluru, Karnataka, India
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Objectives Hyperandrogenism, a key feature of polycystic ovarian syndrome (PCOS), is caused by excess androgen secretion, most commonly of ovarian origin. Although the serum total testosterone (TT) levels have long been used as a traditional measure of hyperandrogenemia in women with PCOS, it is associated with many fallacies due to the fact that a component of TT is linked to sex hormone-binding globulin (SHBG). Recent research has discovered that measuring free testosterone levels and computing the free androgen index (FAI), which is a ratio of TT and SHBG, are better predictors of androgen excess in PCOS. The aim of this meta-analysis is to determine the association of FAI in diagnosing hyperandrogenism and its ability to discriminate PCOS from controls.

Materials and Methods The publicly available databases PubMed, Scopus and Web of Science were searched using MeSH terms, ‘Polycystic Ovarian Syndrome’ OR ‘PCOS’ OR ‘PCOD’ AND ‘Testosterone’ AND ‘Sex Hormone Binding Globulin’ OR ‘SHBG’ to collect the full-text articles for the retrieval of related data of case–control and cross-sectional studies. The studies quality was assessed using the Newcastle–Ottawa scale, and a sub-group analysis and publication bias between the studies was evaluated by funnel plot.

Statistical Analysis The R program (v4.0.3) and R packages ‘metafor’ and ‘dmetar’ were used for statistical analyses of quantitative data and the plots were generated using ‘ggplot2’ package through a comparison of pooled SMD by Egger's linear regression and Beggs-Mazumdar tests.

Results Twenty-four studies involving 7,847 participants including 3,290 controls and 4,557 PCOS were included in the meta-analysis. The pooled data analysis of the included studies showed that the PCOS women had higher FAI than controls, with SMD of 1.56 (95%CI 1.08–2.04; p < 0.01). The publication bias was tested using a funnel plot and Egger's regression asymmetry test, which revealed no risk of publishing bias (p = 0.1727). Additionally, the sub-group meta-analysis of geographic region revealed that FAI levels were more significant in PCOS subjects of Asia and Europe, compared with the American region.

Conclusion Overall, this meta-analysis indicates that FAI could be a reliable marker to differentiate PCOS patients from controls in Asian and European ethnicities.

Keywords

free-androgen index - meta-analysis - polycystic ovarian syndrome - testosterone - sex hormone-binding globulin

Supplementary Material



Publication History

Article published online:
18 November 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Deswal R, Narwal V, Dang A, Pundir CS. The prevalence of polycystic ovary syndrome: a brief systematic review. J Hum Reprod Sci 2020; 13 (04) 261-271
    CrossrefPubMedGoogle Scholar
  • 2 Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29 (02) 181-191
    CrossrefGoogle Scholar
  • 3 Chang S, Dunaif A. Diagnosis of polycystic ovary syndrome: which criteria to use and when?. Endocrinol Metab Clin North Am 2021; 50 (01) 11-23
    CrossrefPubMedGoogle Scholar
  • 4 Zawadzki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Ed. Polycystic Ovary Syndrome. Boston: Blackwell Scientific Boston, MA: Black-well Scientific; 1995: 377-384
    Google Scholar
  • 5 Fauser BCJM. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81 (01) 19-25
    CrossrefPubMedGoogle Scholar
  • 6 Azziz R, Carmina E, Dewailly D. et al; Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91 (11) 4237-4245
    CrossrefPubMedGoogle Scholar
  • 7 Muraleedharan V, Jones TH. Testosterone and the metabolic syndrome. Ther Adv Endocrinol Metab 2010; 1 (05) 207-223
    CrossrefPubMedGoogle Scholar
  • 8 Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 1981; 53 (01) 58-68
    CrossrefPubMedGoogle Scholar
  • 9 Vermeulen A. Physiology of the testosterone-binding globulin in man. Ann N Y Acad Sci 1988; 538 (01) 103-111
    CrossrefPubMedGoogle Scholar
  • 10 Bulun SE. Physiology and Pathology of the Female Reproductive Axis. In: Williams Textbook of Endocrinology Elsevier; 2016: 589-663
    Google Scholar
  • 11 Nestler JE. Obesity, insulin, sex steroids and ovulation. Int J Obes Relat Metab Disord 2000; 24 (Suppl 2): S71-S73
    CrossrefPubMedGoogle Scholar
  • 12 Rao P, Bhide P. Controversies in the diagnosis of polycystic ovary syndrome. Ther Adv Reprod Health 2020; 14: 2633494120913032
    CrossrefPubMedGoogle Scholar
  • 13 Antonio L, Pauwels S, Laurent MR. et al. Free testosterone reflects metabolic as well as ovarian disturbances in subfertile oligomenorrheic women. Int J Endocrinol 2018; 2018: 7956951
    CrossrefPubMedGoogle Scholar
  • 14 Hahn S, Kuehnel W, Tan S. et al. Diagnostic value of calculated testosterone indices in the assessment of polycystic ovary syndrome. Clin Chem Lab Med 2007; 45 (02) 202-207
    CrossrefPubMedGoogle Scholar
  • 15 Carter GD, Holland SM, Alaghband-Zadeh J, Rayman G, Dorrington-Ward P, Wise PH. Investigation of hirsutism: testosterone is not enough. Ann Clin Biochem 1983; 20 (Pt 5): 262-263
    CrossrefPubMedGoogle Scholar
  • 16 Al Kindi MK, Al Essry FS, Al Essry FS, Mula-Abed WAS. Validity of serum testosterone, free androgen index, and calculated free testosterone in women with suspected hyperandrogenism. Oman Med J 2012; 27 (06) 471-474
    CrossrefPubMedGoogle Scholar
  • 17 Pinola P, Piltonen TT, Puurunen J. et al. Androgen profile through life in women with polycystic ovary syndrome: a nordic multicenter collaboration study. J Clin Endocrinol Metab 2015; 100 (09) 3400-3407
    PubMedGoogle Scholar
  • 18 Cho LW, Kilpatrick ES, Jayagopal V, Diver MJ, Atkin SL. Biological variation of total testosterone, free androgen index and bioavailable testosterone in polycystic ovarian syndrome: implications for identifying hyperandrogenaemia. Clin Endocrinol (Oxf) 2008; 68 (03) 390-394
    CrossrefPubMedGoogle Scholar
  • 19 Keevil BG, Adaway J, Fiers T, Moghetti P, Kaufman JM. The free androgen index is inaccurate in women when the SHBG concentration is low. Clin Endocrinol (Oxf) 2018; 88 (05) 706-710
    CrossrefPubMedGoogle Scholar
  • 20 Page MJ, McKenzie JE, Bossuyt PM. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71
    CrossrefPubMedGoogle Scholar
  • 21 Wells G, Shea B, O'Connell D, Peterson J. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa, ONOttawa Hospital Research Institute. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp . Published (2000). Accessed September 10, 2021
    Google Scholar
  • 22 Wang L, Li J. The value of serum-free androgen index in the diagnosis of polycystic ovary syndrome: a systematic review and meta-analysis. J Obstet Gynaecol Res 2021; 47 (04) 1221-1231
    CrossrefPubMedGoogle Scholar
  • 23 Wolf WM, Wattick RA, Kinkade ON, Olfert MD. Geographical prevalence of polycystic ovary syndrome as determined by region and race/ethnicity. Int J Environ Res Public Health 2018; 15 (11) E2589
    CrossrefPubMedGoogle Scholar
  • 24 Merkin SS, Phy JL, Sites CK, Yang D. Environmental determinants of polycystic ovary syndrome. Fertil Steril 2016; 106 (01) 16-24
    CrossrefPubMedGoogle Scholar
  • 25 Rutkowska AZ, Diamanti-Kandarakis E. Polycystic ovary syndrome and environmental toxins. Fertil Steril 2016; 106 (04) 948-958
    CrossrefPubMedGoogle Scholar
  • 26 Ilagan MKCC, Paz-Pacheco E, Totesora DZ, Clemente-Chua LR, Jalique JRK. The modified Ferriman-Gallwey score and hirsutism among Filipino women. Endocrinol Metab (Seoul) 2019; 34 (04) 374-381
    CrossrefPubMedGoogle Scholar
  • 27 Kim JJ, Choi YM. Phenotype and genotype of polycystic ovary syndrome in Asia: ethnic differences. J Obstet Gynaecol Res 2019; 45 (12) 2330-2337
    CrossrefPubMedGoogle Scholar
  • 28 Mehrabadi S, Jahanian SadatmahallehS, Kazemnejad A, Moini A. Association of acne, hirsutism, androgen, anxiety, and depression on cognitive performance in polycystic ovary syndrome: A cross-sectional study. Int J Reprod Biomed 2020; 18 (12) 1049-1058
    PubMedGoogle Scholar
  • 29 Demiïr İ, Guler A, Alarslan P. et al. Fractalkine: an inflammatory chemokine elevated in subjects with polycystic ovary syndrome. Endocrine 2019; 65 (01) 175-183
    CrossrefPubMedGoogle Scholar
  • 30 Sun Y, Li S, Liu H. et al. Association of GPx1 P198L and CAT C-262T Genetic Variations With Polycystic Ovary Syndrome in Chinese Women. Front Endocrinol (Lausanne) 2019; ;10(November): 1-9
    PubMedGoogle Scholar
  • 31 Kogure GS, Silva RC, Miranda-Furtado CL. et al. Hyperandrogenism enhances muscle strength after progressive resistance training, independent of body composition, in women with polycystic ovary syndrome. J Strength Cond Res 2018; 32 (09) 2642-2651
    CrossrefPubMedGoogle Scholar
  • 32 Eksi HaydardedeogluF, Bagir GS, Haydardedeoglu B. et al. Serum betatrophin levels are reduced in patients with full-blown polycystic ovary syndrome. Gynecol Endocrinol 2019; 35 (03) 224-227
    CrossrefPubMedGoogle Scholar
  • 33 Temur M, Calan M, Akşit M. et al. Increased serum neuregulin 4 levels in women with polycystic ovary syndrome: A Case-Control Study. Ginekol Pol 2017; 88 (10) 517-522
    CrossrefPubMedGoogle Scholar
  • 34 Borghi L, Leone D, Vegni E. et al. Psychological distress, anger and quality of life in polycystic ovary syndrome: associations with biochemical, phenotypical andsocio-demographic factors. J Psychosom Obstet Gynecol 2018; 39 (02) 128-137
    CrossrefPubMedGoogle Scholar
  • 35 Shaikh N, Dadachanji R, Meherji P, Shah N, Mukherjee S. Polymorphisms and haplotypes of insulin-like factor 3 gene are associated with risk of polycystic ovary syndrome in Indian women. Gene 2016; 577 (02) 180-186
    CrossrefPubMedGoogle Scholar
  • 36 Jedrzejuk D, Łaczmañski Ł, Milewicz A. et al. Classic PCOS phenotype is not associated with deficiency of endogenous Vitamin D and VDR gene polymorphisms rs731236 (TaqI), rs7975232 (ApaI), rs1544410 (BsmI), rs10735810 (FokI): A case-control study of lower Silesian women. Gynecol Endocrinol 2015; 31 (12) 976-979
    CrossrefPubMedGoogle Scholar
  • 37 Pinola P, Piltonen TT, Puurunen J. et al. Androgen profile through life in women with polycystic ovary syndrome: A nordic multicenter collaboration study. J Clin Endocrinol Metab 2015; 100 (09) 3400-3407
    CrossrefPubMedGoogle Scholar
  • 38 Abu-Hijleh TM, Gammoh E, Al-Busaidi AS. et al. Common Variants in the Sex Hormone-Binding Globulin (SHBG) Gene Influence SHBG Levels in Women with Polycystic Ovary Syndrome. Ann Nutr Metab 2016; 68 (01) 66-74
    CrossrefPubMedGoogle Scholar
  • 39 Song DK, Lee H, Oh JY, Hong YS, Sung YA. FTO gene variants are associated with PCOS susceptibility and hyperandrogenemia in young Korean women. Diabetes Metab J 2014; 38 (04) 302-310
    CrossrefPubMedGoogle Scholar
  • 40 Böttcher B, Stahlhofer KJ, Mattle V, Seeber B, Brezinka C, Wildt L. Ultrasonographic assessment of skin thickness in patients with PCOS-a case-control study. Gynecol Endocrinol 2013; 29 (04) 380-383
    CrossrefPubMedGoogle Scholar
  • 41 Kahal H, Aburima A, Ungvari T. et al. Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity. Clin Endocrinol (Oxf) 2013; 79 (02) 252-258
    CrossrefPubMedGoogle Scholar
  • 42 Hendriks ML, Konig T, Soleman RS. et al. Influence of ovarian manipulation on reproductive endocrinology in polycystic ovarian syndrome and regularly cycling women. Eur J Endocrinol 2013; 169 (04) 503-510
    CrossrefPubMedGoogle Scholar
  • 43 Paltoglou G, Tavernarakis G, Christopoulos P. et al. PON1-108 TT and PON1-192 RR genotypes are more frequently encountered in Greek PCOS than non-PCOS women, and are associated with hyperandrogenaemia. Clin Endocrinol (Oxf) 2013; 79 (02) 259-266
    CrossrefPubMedGoogle Scholar
  • 44 Chen MJ, Han DS, Yang JH, Yang YS, Ho HN, Yang WS. Myostatin and its association with abdominal obesity, androgen and follistatin levels in women with polycystic ovary syndrome. Hum Reprod 2012; 27 (08) 2476-2483
    CrossrefPubMedGoogle Scholar
  • 45 Golbahar J, Al-Ayadhi M, Das NM, Gumaa K. Sensitive and specific markers for insulin resistance, hyperandrogenemia, and inappropriate gonadotrophin secretion in women with polycystic ovary syndrome: A case-control study from Bahrain. Int J Womens Health 2012; 4 (01) 201-206
    CrossrefPubMedGoogle Scholar
  • 46 Misichronis G, Georgopoulos NA, Marioli DJ. et al. The influence of obesity on Androstenedione to Testosterone ratio in women with polycystic ovary syndrome (PCOS) and hyperandrogenemia. Gynecol Endocrinol 2012; 28 (04) 249-252
    CrossrefPubMedGoogle Scholar
  • 47 Mukherjee S, Shaikh N, Khavale S. et al. Genetic variation in exon 17 of INSR is associated with insulin resistance and hyperandrogenemia among lean Indian women with polycystic ovary syndrome. Eur J Endocrinol 2009; 160 (05) 855-862
    CrossrefPubMedGoogle Scholar
  • 48 Lujan ME, Bloski TG, Chizen DR, Lehotay DC, Pierson RA. Digit ratios do not serve as anatomical evidence of prenatal androgen exposure in clinical phenotypes of polycystic ovary syndrome. Hum Reprod 2010; 25 (01) 204-211
    CrossrefPubMedGoogle Scholar
  • 49 Sverrisdóttir YB, Mogren T, Kataoka J, Janson PO, Stener-Victorin E. Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth?. Am J Physiol Endocrinol Metab 2008; 294 (03) E576-E581
    CrossrefPubMedGoogle Scholar
  • 50 Verit FF, Erel O. Oxidative stress in nonobese women with polycystic ovary syndrome: Correlations with endocrine and screening parameters. Gynecol Obstet Invest 2008; 65 (04) 233-239
    CrossrefPubMedGoogle Scholar
  • 51 Codner E, Iñíguez G, Villarroel C. et al. Brief report: Hormonal profile in women with polycystic ovarian syndrome with or without type 1 diabetes mellitus. J Clin Endocrinol Metab 2007; 92 (12) 4742-4746
    CrossrefPubMedGoogle Scholar